Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.
A pancreatic cancer expert on why Revolution Medicines’ study could ‘open up a new era’ of treatment
Revolution Medicines announced a stunning survival benefit for its experimental drug in a Phase 3 pancreatic cancer study ...
Investor's Business Daily on MSN
Why Erasca, up 415% this year amid revolution-tied furor, just lost half its value
Erasca stock crashed Tuesday after a patient in its pancreatic cancer study died following a bout of pneumonia.
REDWOOD CITY, Calif., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today ...
Revolution Medicines, Inc. ((RVMD)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
REDWOOD CITY, Calif., April 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, ...
Revolution Medicines' experimental oral drug helped patients with pancreatic cancer live nearly twice as long as those ...
REDWOOD CITY, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results